image
Healthcare - Biotechnology - OTC - US
$ 0.024
-1.54 %
$ 1.81 M
Market Cap
-0.11
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one GRTX stock under the worst case scenario is HIDDEN Compared to the current market price of 0.024 USD, Galera Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one GRTX stock under the base case scenario is HIDDEN Compared to the current market price of 0.024 USD, Galera Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one GRTX stock under the best case scenario is HIDDEN Compared to the current market price of 0.024 USD, Galera Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart GRTX

image
$0.1$0.1$0.1$0.1$0.0$0.0$0.0$0.0$0.0$0.0$0.0$0.0$0.0$0.0$0.0$0.015 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '25
FINANCIALS
0 REVENUE
0.00%
-20.2 M OPERATING INCOME
57.06%
-19 M NET INCOME
67.91%
-12.1 M OPERATING CASH FLOW
72.92%
-46 K INVESTING CASH FLOW
-0.17%
2.22 M FINANCING CASH FLOW
-92.94%
0 REVENUE
0.00%
-5.47 M OPERATING INCOME
7.48%
-4.93 M NET INCOME
11.65%
-2.34 M OPERATING CASH FLOW
-31.15%
-50 K INVESTING CASH FLOW
-1250.00%
2.22 M FINANCING CASH FLOW
0.00%
Balance Sheet Galera Therapeutics, Inc.
image
Current Assets 10 M
Cash & Short-Term Investments 8.29 M
Receivables 635 K
Other Current Assets 1.08 M
Non-Current Assets 100 K
Long-Term Investments 0
PP&E 0
Other Non-Current Assets 100 K
82.06 %6.29 %10.66 %Total Assets$10.1m
Current Liabilities 1.67 M
Accounts Payable 1.28 M
Short-Term Debt 0
Other Current Liabilities 391 K
Non-Current Liabilities 152 M
Long-Term Debt 0
Other Non-Current Liabilities 152 M
98.92 %Total Liabilities$153.8m
EFFICIENCY
Earnings Waterfall Galera Therapeutics, Inc.
image
Revenue 0
Cost Of Revenue 3.84 M
Gross Profit -3.84 M
Operating Expenses 14.2 M
Operating Income -20.2 M
Other Expenses -1.2 M
Net Income -19 M
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)0(4m)(4m)(14m)(20m)1m(19m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
13.19% ROE
13.19%
-187.67% ROA
-187.67%
-236.47% ROIC
-236.47%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Galera Therapeutics, Inc.
image
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)2018201820192019202020202021202120222022202320232024202420252025
Net Income -19 M
Depreciation & Amortization 20 K
Capital Expenditures 0
Stock-Based Compensation 2.54 M
Change in Working Capital -2.13 M
Others 5.87 M
Free Cash Flow -12.1 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Galera Therapeutics, Inc.
image
GRTX has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 9
6. Ownership
Insider Ownership Galera Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
4.83 K USD 1
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
500 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Galera Therapeutics completes acquisition of Nova Pharmaceuticals Galera's development strategy shifts from toxicity reduction to anti-cancer therapeutics, with three trials in patients with highly resistant subsets of advanced breast cancer. globenewswire.com - 4 months ago
Galera Announces Board Approval of Complete Liquidation and Dissolution MALVERN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company historically focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that its Board of Directors has approved a Plan of Liquidation and Dissolution (Plan of Dissolution), which provides for the dissolution of the Company under Delaware law, and plans to seek stockholder approval of the Plan of Dissolution at a special meeting of stockholders to be held on or around October 17, 2024. globenewswire.com - 9 months ago
Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates MALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the first quarter ended March 31, 2024, and provided recent corporate updates. globenewswire.com - 1 year ago
Galera Adopts Limited Duration Stockholder Rights Agreement MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that its Board of Directors (the “Board”) has unanimously resolved to adopt a limited duration stockholder rights agreement (the “Rights Agreement”) to protect stockholder interests. globenewswire.com - 1 year ago
Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates Company continues to evaluate strategic options to maximize shareholder value Company continues to evaluate strategic options to maximize shareholder value globenewswire.com - 1 year ago
Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates FDA confirms need for new trial for avasopasem; GRECO trials with rucosopasem to be discontinued Company evaluating potential strategic options to optimize shareholder value MALVERN, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the third quarter ended September 30, 2023 and provided recent corporate updates. globenewswire.com - 1 year ago
Galera Announces Receipt of Type A Meeting Minutes and Strategic Update FDA confirms need for new trial for avasopasem for severe oral mucositis (SOM) GRECO-2 trial did not pass futility analysis; Company will discontinue both GRECO trials Company reviewing potential strategic alternatives to maximize shareholder value MALVERN, Pa., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that it has received official meeting minutes from the Type A meeting with the United States Food and Drug Administration (FDA) held September 28, 2023 in which the FDA reiterated the need for an additional Phase 3 trial of avasopasem manganese (avasopasem) for radiotherapy-induced SOM. globenewswire.com - 1 year ago
Galera Schedules Type A Meeting with FDA to Discuss Next Steps for Avasopasem MALVERN, Pa., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that a Type A Meeting has been scheduled for September 28, 2023 with the U.S. Food and Drug Administration (FDA) regarding the Complete Response Letter (CRL) received for the Company's New Drug Application (NDA) for avasopasem manganese (avasopasem). The FDA is expected to issue written meeting minutes approximately 30 days following the meeting. globenewswire.com - 1 year ago
Top 5 Health Care Stocks That May Explode In Q3 - BioVie (NASDAQ:BIVI), Galera Therapeutics (NASDAQ:GRTX) The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. benzinga.com - 1 year ago
All You Need to Know About Galera Therapeutics, Inc. (GRTX) Rating Upgrade to Buy Galera Therapeutics, Inc. (GRTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com - 1 year ago
3 Biotech Stocks Poised to Beat Q2 Earnings Estimates We look at a few biotech companies, LEGN, KOD, GRTX, which are poised to beat second-quarter earnings estimates. zacks.com - 1 year ago
Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates Company received Complete Response Letter from FDA for avasopasem and intends to request Type A meeting with FDA to discuss potential next steps globenewswire.com - 1 year ago
8. Profile Summary

Galera Therapeutics, Inc. GRTX

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 1.81 M
Dividend Yield 0.00%
Description Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Contact 2 West Liberty Boulevard, Malvern, PA, 19355 https://www.galeratx.com
IPO Date Nov. 7, 2019
Employees 3
Officers Dr. J. Mel Sorensen M.D. Chief Executive Officer, President & Chairman Mr. Joel F. Sussman CMA, CPA Chief Accounting Officer, Secretary & Treasurer